Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price17.51 USD
Fair value21.00
Ethical score70.0/100
Our investment reviews on this name
2026-08-09Read Distribution19.22-8.9% to today ✓
2026-07-02Read Markup25.71-31.9% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
PROCEPT BioRobotics Corporation holds its Distribution at $17.51. The statistical read favours the sellers, held for 11 days.
As held on the ledger · 2026-10-06
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 11 days
Price at the screen
$17.51
Valuation
N/A trailing · -15.19 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.92
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
15.45%
Below 33%
Interest-bearing debt is just 15.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
72.83%
Below 49%
Money owed to the company is 72.8% of assets, above the 49% limit.
Fail
Revenue purity
3.97%
Below 5%
Only 4.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
PROCEPT BioRobotics's business is fine, but its receivables are about 73% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-10-07. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-06 screen. The gold marker is the market price at the same screen. A 19.9% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Hold. The average target sits +20% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Robotic urology tool still bleeding cash heavily
Picture a surgeon firing up a new robotic water jet to treat prostate issues with less damage than older methods. PROCEPT BioRobotics has built exactly that with its AquaBeam system, and revenue is rising 20 percent as hospitals adopt it. Yet the business still posts a 32 percent negative profit margin and negative 28 percent return on equity, so every extra sale widens the cash hole rather than filling it.
Analysts like the story and set targets near 30 dollars against the current 19 dollar price, but we pass. Forward earnings sit at a negative 21.6 times multiple because there are no earnings yet, and the moat remains unknown in a field already crowded with bigger surgical robotics players. The ethical screen clears, yet the numbers show a company that needs years of further investment before it might turn a steady profit.
High execution risk sits in scaling a capital intensive medical device across hospitals while currency and reimbursement swings can hit margins fast. Peak spending often coincides with the lowest multiples in this sector, which is usually a warning rather than a bargain. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PRCT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Distribution$19.30-6.3%Entry 6
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 55%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (9 analysts) rates it buy, with a mean price target of $30.
2026-09-10Distribution$20.60+7.2%Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 7.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 55%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (9 analysts) rates it buy, with a mean price target of $30.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 25.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 55%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (9 analysts) rates it buy, with a mean price target of $30.
2026-07-18Markup$25.71+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 55%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (9 analysts) rates it buy, with a mean price target of $30.
2026-07-03Markup$25.71+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$25.71Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
